Overview

Posaconazole vs Itraconazole in Preventing IFD Post-HSCT

Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
0
Participant gender:
All
Summary
Invasive Fungal Disease (IFD) after haematopoietic stem cell transplantation (HSCT) remain a clinical challenge.The studay aims to compare the efficacy and safety of posaconazole oral suspension vs itraconazole oral solution in preventing IFD post-HSCT.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fujian Medical University
Treatments:
Antifungal Agents
Clotrimazole
Hydroxyitraconazole
Itraconazole
Miconazole
Posaconazole
Criteria
Inclusion Criteria:

- Signed written informed consent Aged ≥13 years Patients undergoing hematopoietic stem
cell transplantation. Cardiac: Left ventricular ejection fraction ≥ 50% Adequate renal
and hepatic function Performance status: Karnofsky ≥ 70%

Exclusion Criteria:

- Pregnant or lactating females Any co-morbidity precluding the administration
ofposaconazole or itraconazole